SCHEMBL2038233

SCHEMBL2038233

Cc1ccc(S(=O)(=O)SSS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.64
G6PD P11413 2/20 0.59
GAA P10253 2/20 0.59
CA1 P00915 3/20 0.54
CA2 P00918 3/20 0.54
CA12 O43570 1/20 0.54
CA3 P07451 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
TLR9 Q9NR96 1/20 0.52
BCHE P06276 6/20 0.52
ACHE P22303 6/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 2/20 0.48
MMP1 P03956 1/20 0.48
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11343468 0.90 DNMT1 (0.59) DNMT1G6PDGAACA1CA2
SCHEMBL30537780 0.86 DNMT1 (0.55) DNMT1G6PDGAACA1CA2
SCHEMBL733650 0.84 DNMT1 (0.64) DNMT1G6PDGAACA1CA2
SCHEMBL17639946 0.83 G6PD (0.53) DNMT1G6PDGAACA1CA2
SCHEMBL30120630 0.83 DNMT1 (0.52) DNMT1G6PDGAACA1CA2
SCHEMBL7271430 0.82 DNMT1 (0.61) DNMT1G6PDGAACA1CA2
SCHEMBL29384596 0.80 DNMT1 (0.59) DNMT1G6PDGAACA1CA2
SCHEMBL16693835 0.80 DNMT1 (0.59) DNMT1G6PDGAACA1CA2
SCHEMBL29355952 0.80 DNMT1 (0.59) DNMT1G6PDGAACA1CA2
SCHEMBL16471369 0.80 DNMT1 (0.59) DNMT1G6PDGAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590115-B2 Technologies useful for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2026-03-31 US disclosed
US-20260008806-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD (SG) 2026-01-08 US disclosed
US-12435105-B2 Technologies for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2025-10-07 US disclosed
US-20240327448-A1 LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS OLIX US, INC. 2024-10-03 US disclosed
WO-2024173777-A1 LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS OLIX US, INC. (US) 2024-08-22 WO disclosed
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
US-20230089442-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-03-23 US disclosed
US-11608355-B2 Technologies for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2023-03-21 US disclosed
CN-113748116-A Techniques useful for oligonucleotide preparation 波涛生命科学有限公司 2021-12-03 CN disclosed
US-20210309690-A1 OLIGONUCLEOTIDE SYNTHESIS ROCHE INNOVATION CT COPENHAGEN AS (DK) 2021-10-07 US disclosed
US-6384209-B1 HIGHLY EFFIENT PROCESS BY CONTACTING OLIGONUCLEOTIDE HAVING INTERNUCLEOSIDE LINKAGE OF A PHOSPHOROUS III ATOM WITH A REAGENT OF DEFINED STRUCTURE; REAGENTS ARE INEXPENSIVE TO MAKE AND STABLE IN STORAGE AVECIA BIOTECHNOLOGY, INC. (GB) 2002-05-07 US disclosed
WO-2002020544-A1 PROCESS FOR PREPARING PEPTIDE DERIVATIZED OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2002-03-14 WO disclosed
US-20020010326-A1 NOVEL SULFURIZING REAGENT 3-PHENYL-1,2,4-DITHIAZOLINE-5-ONE NITTO DENKO AVECIA, INC. 2002-01-24 US disclosed
US-6096881-A Sulfur transfer reagents for oligonucleotide synthesis HYBRIDON, INC. (US) 2000-08-01 US disclosed
EP-0986571-A1 NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS HYBRIDON, INC. (US) 2000-03-22 EP disclosed
WO-1998054198-A9 NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS HYBRIDON INC (US) 1999-04-01 WO disclosed
WO-1999003873-A2 NOVEL SULFURIZING REAGENT 3-PHENYL-1,2,4-DITHIAZOLINE-5-ONE HYBRIDON, INC. (US) 1999-01-28 WO disclosed
WO-1998054198-A1 NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS HYBRIDON, INC. (US) 1998-12-03 WO disclosed
WO-1998049181-A1 NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS HYBRIDON, INC. (US) 1998-11-05 WO disclosed
WO-1998008809-A1 NOVEL SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS HYBRIDON, INC. (US) 1998-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309690-A1 OLIGONUCLEOTIDE SYNTHESIS RNGTT, RTCB, TYMS DNMT1 163/4885G6PD 811/4885GAA 1590/4885
US-11608355-B2 Technologies for oligonucleotide preparation POLRMT, DCLRE1B, RNGTT DNMT1 131/4885G6PD 4435/4885GAA 687/4885
US-20020010326-A1 NOVEL SULFURIZING REAGENT 3-PHENYL-1,2,4-DITHIAZOLINE-5-ONE BPNT1, DNTT, TST DNMT1 998/4885G6PD 2814/4885GAA 3692/4885
US-20260008806-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION RNGTT, RNMT, NSUN2 DNMT1 56/4885G6PD 3661/4885GAA 4343/4885
US-12435105-B2 Technologies for oligonucleotide preparation POLRMT, DCLRE1B, RNGTT DNMT1 131/4885G6PD 4435/4885GAA 687/4885
US-20240327448-A1 LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS POLRMT, NSUN2, RNGTT DNMT1 116/4885G6PD 2451/4885GAA 2579/4885
US-20230089442-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, POLM DNMT1 103/4885G6PD 4265/4885GAA 786/4885
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT DNMT1 131/4885G6PD 4435/4885GAA 687/4885
US-12590115-B2 Technologies useful for oligonucleotide preparation NOP2, RNGTT, NSUN2 DNMT1 163/4885G6PD 2949/4885GAA 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.